NCT06812702Completed
Parkinson's Disease Biomarker Study
A Multi-site Longitudinal Cohort Study of Prodromal and Clinical Parkinson'sDisease
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
The primary objective of this study is to determine whether data acquired from a remote monitoring approach can reliably identify and track motor symptoms in prodromal PD and clinical PD. The study is a one-year longitudinal biomarker study recruiting idiopathic RBD patients, Parkinson's Disease patient and healthy controls. All participants receive a smartphone with the Roche PD Mobile Application, complete a number of active tests daily and their movements will be remotely monitored. Participants will undergo additional neurological exams and DaT-SPECT and MRI imaging in the study. A second objective of this study will be to validate an immunohistochemistry skin biopsy assay for the detection of pathological alpha-synuclein diagnostic of PD, in the peripheral nerves of the skin.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 230 (actual)
- First submitted
- 2 Feb 2025
- Start date
- 5 Mar 2019
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Ronald Postuma
- Diseases
- Parkinson disease
- NCT number
- NCT06812702
What you commit to
- Study type: Observational
- Participants enrolled: 230
- From 5 Mar 2019 to the primary completion date, 31 Dec 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- participation in interventional clinical study within 3 months of screening, moderate to severe depression in judgement of the investigator, any concomitant disease, condition or treatment which may interfer with the conduct of study (determined by investigator), additional group-specific exclusion criteria
Who the study is looking for
- signed consent form, male or female over age 40, ability to follow protocol, additional group-specific inclusion criteria
Age in the registry: 40 years to - · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier de l'Universite de Montreal (CHUM) Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| The Neuro Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| Centre de recherche du CHU de Québec-Université Laval (CHUQ) Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
| Pacific Parkinson's Research Centre Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.